Services

Online Inquiry

Your Name

Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

siRNA Conjugation to Targeting Ligands

At Protheragen BioNucleics, we specialize in advancing the development of oligonucleotide therapeutics. Our comprehensive services encompass Oligonucleotide Drugs CRO, Oligonucleotide Modification Service, siRNA Modification Service, and siRNA End Modification. We are committed to enhancing the efficacy of small interfering RNA (siRNA) by employing cutting-edge conjugation strategies to improve targeted delivery.

Overview of siRNA Conjugation to Targeting Ligands

siRNA holds immense potential in gene therapy due to its ability to specifically silence gene expression. However, a significant challenge lies in delivering siRNA molecules directly to the desired cells or tissues while avoiding degradation and off-target effects. Conjugating siRNA to targeting ligands has emerged as an effective solution to this problem.

By attaching siRNA to molecules such as antibodies, aptamers, or peptides, we can facilitate receptor-mediated endocytosis, enhance cellular uptake, and improve stability in the bloodstream. This method ensures that the siRNA reaches the specific site of action, thereby increasing therapeutic efficacy and reducing potential side effects. The choice of targeting ligand is crucial and depends on the specific application and target cells.

Our Services in siRNA Conjugation to Targeting Ligands

At Protheragen BioNucleics, we offer a suite of services tailored to optimize siRNA delivery through precise conjugation techniques. Our expertise includes but is not limited to antibody-siRNA conjugations, aptamer attachment, and peptide conjugation.

Antibody-siRNA Conjugates

We specialize in creating antibody-siRNA conjugates that combine the specificity of monoclonal antibodies with the gene-silencing capability of siRNA. This approach allows for targeted delivery to cells expressing specific antigens.

Custom Antibody Selection: We assist in selecting or engineering antibodies that precisely target your cells of interest.
Site-specific Conjugation: Utilizing advanced chemistries to attach siRNA molecules without affecting the antibody's binding sites.
Linker Technologies: Incorporation of cleavable linkers that release siRNA within the target cells, ensuring efficient gene silencing.
Validation and Quality Control: Rigorous testing to confirm the functionality of the conjugate, including binding affinity and gene knockdown efficiency.

Aptamer Attachment

Our aptamer-siRNA conjugation service leverages the benefits of aptamers—short, single-stranded nucleic acids that can fold into complex structures for high-affinity binding.

Aptamer Design and Synthesis: Custom design of aptamers specific to your target molecules or cells.
Conjugation Strategies: Chemical linkage of aptamers to siRNA without compromising structural integrity.
Optimization: Fine-tuning spacer lengths and linkers to maximize binding and internalization.
Functional Assessment: Ensuring that the conjugated siRNA retains its silencing activity post-conjugation.

Peptide Conjugation

Peptide-siRNA conjugation enhances intracellular delivery by exploiting cell-penetrating peptides (CPPs) or receptor-targeting peptides.

Peptide Selection: Identification of peptides with optimal properties for membrane translocation or receptor specificity.
Efficient Coupling Methods: Utilizing strategies like thiol-maleimide chemistry for stable conjugate formation.
Endosomal Escape Enhancement: Incorporation of features that facilitate the release of siRNA into the cytoplasm.
Stability Studies: Assessing the conjugate's resistance to enzymatic degradation in biological fluids.

Customized Conjugation Solutions

Recognizing that one size does not fit all, we provide bespoke solutions tailored to your project's unique requirements.

Alternative Ligands: Conjugation with small molecules, lipids, or nanoparticles for specialized applications.
Dual-targeting Strategies: Designing conjugates that target multiple receptors for enhanced specificity.
Scale-up and Manufacturing: Capability to scale processes from research to production.
Regulatory Support: Guidance on compliance with regulatory standards for therapeutic development.

Frequently Asked Questions

Q1: How do you ensure the stability of the siRNA-ligand conjugates in vivo?

We employ advanced linker chemistries and protective modifications to enhance the stability of siRNA-ligand conjugates against nuclease degradation. This includes the use of phosphorothioate backbones, 2'-O-methyl modifications, and the incorporation of polyethylene glycol (PEG) chains to shield the siRNA from enzymatic attack.

Q2: Can you modify existing siRNA sequences for better conjugation compatibility?

Yes, we offer modification services for existing siRNA sequences to introduce functional groups or linkers that facilitate conjugation without affecting gene-silencing activity. Our team ensures that modifications are strategically placed to maintain the integrity of the active siRNA region.

Our services and products are exclusively for authorized organizations in research, development, or manufacturing and are not intended for direct use by individuals or patients or as medical advice, diagnosis, or treatment.